Viridian Therapeutics reports Q2 EPS ($1.27), consensus ($1.29)

Cash, cash equivalents, and short-term investments were $334.3 million as of June 30, 2023, compared with $373.9 million as of March 31, 2023. The Company believes that its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the second half of 2025. “Last month, we established proof-of-concept for VRDN-001 in patients with chronic TED, marking an exciting milestone for the Company and building on the compelling data we previously reported in active TED. VRDN-001 demonstrated profound clinical activity in chronic TED patients after only two infusions, confirming this candidate’s ability to potentially be an effective therapy in active and chronic TED,” said Scott Myers, President and CEO of Viridian Therapeutics. “We are also quickly advancing our potential first-in-class subcutaneous TED program and are proud to announce that our Phase 1 trial for VRDN-001 SC in healthy volunteers is fully enrolled. In addition, our Phase 1 trial for VRDN-003 SC has been initiated and is now enrolling healthy volunteers.”